Representative drug susceptibility patterns for guiding design of re‐treatment regimens for multidrug‐resistant tuberculosis in Iran
作者： Payam Tabarsi , Azar Nooraki , Mehdi Mirsaeidi , Majid Amiri , Parvaneh Baghaei
DOI: 10.1111/J.1440-1843.2007.01201.X
关键词:
摘要: Background and objective: The prevalence of multidrug-resistant tuberculosis (MDR-TB) has increased substantially in the past 20 years, however, there are no data specific to Iran. This study investigated patients suspected have MDR-TB, attending TB referral hospital Iran. Methods: All having MDR-TB on admission period 2003–2005 were included this study. Sputum from all was tested for smear culture, drug sensitivity testing performed using proportion method. Patients categorized into three groups based their history medical treatment. Group I consisted with CAT regimen failure; II a failure III comprised more than two courses irregular anti-TB regimen. Results: There 105 recruited; 32 I, 53 20 III. significant differences between resistance first-line drugs. Fifty-five diagnosed MDR-TB. 56% (18 cases) group 49% (26 55% (11 No difference pattern observed groups. Conclusion: high lack response treatment indicates that antibiotic is essential failure.
elsevier.com
sci-hub.se 参考文章(23)
Nardell Ea, Furin J, Mitnick Cd, Socci Ar, Becerra Mc, Bonilla C, Bayona J, Mukherjee Js, Seung Kj, Farmer Pe, Rich Ml, Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. International Journal of Tuberculosis and Lung Disease. ,vol. 10, pp. 290- 296 ,(2006)
A. Sloutsky, M. C. Becerra, J. Bayona, J. Y. Kim, B. Werner, S. S. Shin, P. E. Farmer, M. E. Wilson, J. Freeman, J. J. Furin, R. Timperi, M. Pagano, Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease. ,vol. 4, pp. 108- 114 ,(2000)
Portaels F, Kluge H, Demeulenaere T, Kimerling Me, Vezhnina N, Iacovazzi T, Matthys F, Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. International Journal of Tuberculosis and Lung Disease. ,vol. 3, pp. 451- 453 ,(1999)
C. W. H. Havard, Current medical treatment ,(1970)
Pedro G Suárez, Katherine Floyd, Jaime Portocarrero, Edith Alarcón, Elisabetta Rapiti, Gilbert Ramos, Cesar Bonilla, Ivan Sabogal, Isabel Aranda, Christopher Dye, Mario Raviglione, Marcos A Espinal, None, Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru The Lancet. ,vol. 359, pp. 1980- 1989 ,(2002) , 10.1016/S0140-6736(02)08830-X
D.C.S HUTCHISON, F.A DROBNIEWSKI, H.J MILBURN, Management of multiple drug-resistant tuberculosis. Respiratory Medicine. ,vol. 97, pp. 65- 70 ,(2003) , 10.1053/RMED.2002.1412
Parisa Farnia, Mohammad Reza Masjedi, Ali Akbar Velayati, Seyed Mehdi Mirsaeidi, Payam Tabarsi, Kaveh Khoshnood, Majid Valiollah Pooramiri, Ali Rowhani-Rahbar, Seyed Davood Mansoori, Heydar Masjedi, Soheyla Zahirifard, Foroozan Mohammadi, Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran International Journal of Infectious Diseases. ,vol. 9, pp. 317- 322 ,(2005) , 10.1016/J.IJID.2004.09.012
L. Rigouts, F. Portaels, DNA fingerprints of Mycobacterium tuberculosis do not change during the development of resistance to various antituberculous drugs. Tubercle and Lung Disease. ,vol. 75, pp. 160- ,(1994) , 10.1016/0962-8479(94)90051-5
E. D Chan, Current medical treatment for tuberculosis BMJ. ,vol. 325, pp. 1282- 1286 ,(2002) , 10.1136/BMJ.325.7375.1282
Marcos A. Espinal, The global situation of MDR-TB Tuberculosis. ,vol. 83, pp. 44- 51 ,(2003) , 10.1016/S1472-9792(02)00058-6